These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32026409)

  • 21. Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV
    Kang J; Lee JS; Lee SW; Lee JB; Oh YM
    Respir Res; 2021 Feb; 22(1):55. PubMed ID: 33579288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Relationship Between Clinical Phenotypes and Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stages/Groups in Patients With Chronic Obstructive Pulmonary Disease.
    Pandey AK; Verma AK; Singh A; Kant S; Dixit RK; Chaudhary SC; Bajpai J; Prakash V; Verma UP
    Cureus; 2022 Dec; 14(12):e32116. PubMed ID: 36601200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England.
    Sansbury LB; Rothnie KJ; Bains C; Compton C; Anley G; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2021; 16():2591-2604. PubMed ID: 34552325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD).
    Rebordosa C; Plana E; Aguado J; Thomas S; García-Gil E; Perez-Gutthann S; Castellsague J
    Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):126-133. PubMed ID: 29740896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment Transitions in Chronic Obstructive Pulmonary Disease: Retrospective Analyses of US and UK Healthcare Databases.
    Bloom CI; Montonen J; Jöns O; Garry EM; Bhatt SP
    Pulm Ther; 2022 Mar; 8(1):75-93. PubMed ID: 35015269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score-matched cohort analysis.
    Muro S; Suzuki M; Nakamura S; Wang JR; Garry EM; Sakamoto W; de Souza S
    Respir Res; 2021 Jun; 22(1):180. PubMed ID: 34140019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification.
    Jones PW; Adamek L; Nadeau G; Banik N
    Eur Respir J; 2013 Sep; 42(3):647-54. PubMed ID: 23258783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
    Sethi S; Palli SR; Bengtson LGS; Buysman EK; Clark B; Sargent A; Shaikh A; Ferguson GT
    J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
    [No Abstract]   [Full Text] [Related]  

  • 30. A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications.
    Ding B; Small M; Holmgren U
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1527-1537. PubMed ID: 28579771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.
    Price D; West D; Brusselle G; Gruffydd-Jones K; Jones R; Miravitlles M; Rossi A; Hutton C; Ashton VL; Stewart R; Bichel K
    Int J Chron Obstruct Pulmon Dis; 2014; 9():889-904. PubMed ID: 25210450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COPD patients' characteristics, usual care, and adherence to guidelines: the Greek UNLOCK study.
    Tsiligianni I; Kampouraki M; Ierodiakonou D; Poulonirakis I; Papadokostakis P
    Int J Chron Obstruct Pulmon Dis; 2019; 14():547-556. PubMed ID: 30880944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy.
    Palli SR; Zhou S; Shaikh A; Willey VJ
    J Manag Care Spec Pharm; 2021 May; 27(5):625-637. PubMed ID: 33779246
    [No Abstract]   [Full Text] [Related]  

  • 34. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
    Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
    Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Effectiveness of Initial LAMA versus LABA in COPD: Real-World Cohort Study.
    Suissa S; Dell'Aniello S; Ernst P
    COPD; 2021 Feb; 18(1):1-8. PubMed ID: 33569990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach.
    Singh D; Litewka D; Páramo R; Rendon A; Sayiner A; Tanni SE; Acharya S; Aggarwal B; Ismaila AS; Sharma R; Daley-Yates P
    Adv Ther; 2023 Oct; 40(10):4282-4297. PubMed ID: 37382864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV
    Chai CS; Ng DL; Bt Mos S; Ibrahim MAB; Tan SB; Pang YK; Liam CK
    BMC Pulm Med; 2023 Apr; 23(1):150. PubMed ID: 37118725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Respiratory symptoms (COPD Assessment Test and modified Medical Research Council dyspnea scores) and GOLD-ABCD COPD classification: the LASSYC study.
    Oca MM; Varela MVL; Menezes AMB; Wehrmeister FC; Ramirez L; Miravitlles M
    J Bras Pneumol; 2021; 47(5):e20210156. PubMed ID: 34787288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.